Overview

Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics

Status:
Not yet recruiting
Trial end date:
2022-06-02
Target enrollment:
Participant gender:
Summary
the investigators hypothesized that Nalbuphine may be alternative pharmacological agent for prevention of emergence agitation in pediatrics who will be scheduled for elective lower abdominal surgical procedures (inguinal hernia repair and hypospadias) during sevoflurane anesthesia
Phase:
Phase 4
Details
Lead Sponsor:
Alexandria University
Treatments:
Dexmedetomidine
Nalbuphine